Peter Lawson
Stock Analyst at Barclays
(1.16)
# 3,391
Out of 4,829 analysts
105
Total ratings
32.1%
Success rate
-15.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.93 | -32.81% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $6.10 | +80.33% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $6.59 | +142.98% | 8 | May 2, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $40 → $15 | $8.59 | +74.62% | 2 | May 1, 2025 | |
| SWTX SpringWorks Therapeutics | Downgrades: Equal-Weight | $63 → $47 | $46.17 | +1.81% | 4 | Apr 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $14 | $8.78 | +59.45% | 7 | Apr 23, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $22 → $5 | $1.84 | +172.48% | 6 | Apr 14, 2025 | |
| BMEA Biomea Fusion | Maintains: Equal-Weight | $11 → $3 | $1.70 | +76.47% | 5 | Apr 2, 2025 | |
| TCRX TScan Therapeutics | Maintains: Overweight | $14 → $3 | $1.33 | +126.42% | 2 | Mar 7, 2025 | |
| GERN Geron | Maintains: Overweight | $9 → $4 | $1.30 | +207.69% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $29 | $36.67 | -20.92% | 5 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $41.77 | +43.64% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.08 | +451.95% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $10.97 | +200.82% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $29.05 | +127.23% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.58 | +406.33% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $101.80 | +3.14% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $10.04 | +208.76% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.82 | +117.39% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $1.14 | +1,045.37% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $1.12 | +792.86% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.31 | +222.48% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.87 | +474.07% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $120 | $6.18 | +1,841.75% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $1.75 | +100.00% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $80.54 | +353.19% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $28.78 | +59.83% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.67 | +4,377.61% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.63 | +2,660.74% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $37.73 | +19.28% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.71 | +9,803.79% | 1 | Jul 14, 2017 |
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.93
Upside: -32.81%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $6.10
Upside: +80.33%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $6.59
Upside: +142.98%
Bicycle Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $8.59
Upside: +74.62%
SpringWorks Therapeutics
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $63 → $47
Current: $46.17
Upside: +1.81%
Arcus Biosciences
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $8.78
Upside: +59.45%
Iovance Biotherapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $22 → $5
Current: $1.84
Upside: +172.48%
Biomea Fusion
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.70
Upside: +76.47%
TScan Therapeutics
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.33
Upside: +126.42%
Geron
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.30
Upside: +207.69%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $36.67
Upside: -20.92%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $41.77
Upside: +43.64%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.08
Upside: +451.95%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $10.97
Upside: +200.82%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $29.05
Upside: +127.23%
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.58
Upside: +406.33%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $101.80
Upside: +3.14%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $10.04
Upside: +208.76%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.82
Upside: +117.39%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $1.14
Upside: +1,045.37%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $1.12
Upside: +792.86%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.31
Upside: +222.48%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.87
Upside: +474.07%
Aug 5, 2022
Maintains: Overweight
Price Target: $210 → $120
Current: $6.18
Upside: +1,841.75%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.75
Upside: +100.00%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $80.54
Upside: +353.19%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $28.78
Upside: +59.83%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.67
Upside: +4,377.61%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.63
Upside: +2,660.74%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $37.73
Upside: +19.28%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $0.71
Upside: +9,803.79%